GlassScriptPhysician profile
Sajeeb Adhikary
NPI 1700204609
$1,546.43
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $455 · 2021: $713 · 2022: $21.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $367.59 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.10 | 2020-2022 | |
| Allergan, INC. | $187.04 | 2019-2020 | |
| Alkermes, INC. | $176.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $172.08 | 2019-2021 | |
| Abbvie INC. | $113.89 | 2021 | |
| Neurocrine Biosciences, INC. | $93.37 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $81.30 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $55.40 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $30.15 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.47 | 2021 | |
| Indivior INC. | $14.82 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeeb Adhikary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.